Phase II Trial of CPX (Cytarabine:Daunorubicin) Liposome 
Injection in Patients >/=60 Years of Age With AML Previously Untreated By Intensive Chemotherapy  
 
Study ID: [REMOVED] 
 Document Date: 25 -JUN -2018 
 
 Protocol CEL11001 
 
PHASE II TRIAL OF CPX-351 (CYTARABINE:DAUNORUBICIN) LIPOSOME 
INJECTION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA >60 YEARS 
OF AGE WHO HAVE NOT BEEN TREATED WITH INTENSIVE CHEMOTHERAPY   
Sponsor 
Weill Cornell Medicine 
 
Investigator Initiated Trial 
  
Principal Investigator 
Ellen Ritchie 
Weill Cornell Medical College 
525 East 68
th Street 
New York, NY  10065 
646-962-2700 
Fax 646-962-5115 
ritchie@med.cornell.edu 
 
Co-investigators 
Gail Roboz 
Sangmin Lee 
Pinkal Desai 
Michael Samuel 
Jeffrey Ball 
 
Confidential 
 
Statistician 
Lynn Shemanski 
  
Version 4.0 dated 09-FEB-2018 
 
IND# 136240 
CPX-351 
 
 
    
 
 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 2 of 50   
 
 
Not for Publication  The information in this document contains trade secr ets and commercial information that are privileged or 
confidential and may not be disclosed unless such disclosu re is required by federal or state law or regulations. 
In any event, persons to whom th e information is disclosed must be informed that the information is 
privileged or confidential and may not be further disclo sed by them. These restrictions on disclosure will 
apply equally to all future information supplied to you which is indicated as privileged or confidential.  
    
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 3 of 50  PROTOCOL SYNOPSIS 
Title: 
PHASE II TRIAL OF CPX -351—(CYTARABINE:DAUNORUBICIN) LIPOSOME 
INJECTION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA >60 YEARS 
OF AGE WHO HAVE NOT BEEN TREATED WITH INTENSIVE 
CHEMOTHERAPY  
 
Sponsor: Weill Cornell Medicine  
Investigator Initiated Trial:  
Principal Investigator: Ellen Ritchie  
Weill-Cornell Medical Center 
Objectives: 
Primary  
x To assess the suitability of CPX-351 as first intensive therapy in older (age  ≥60 
years) patients with AML based on safety and efficacy.  The primary efficacy 
endpoint will be overall survival (OS).  The primary safety endpoint will be 30 -day 
mortality.   
 
Secondary  
x To assess efficacy by response (CR, CRp, CRi, and CR+CRp+CRi)) rate, response 
duration, and Event Free Survival (EFS) 
x To assess safety by 30- day mortality, serious adverse events (SAE) and adverse 
event frequency and severity 
x To assess QOL using FACT-LEU 
x To assess the relationship of cognitive function to outcome using the Blessed 
Orientation-Memory- Concentration Test and the Montreal Cognitive Assessment 
x To confirm the safety of CPX-351 as a post-remission (consolidation) therapy  
x To supplement efficacy assessment by determining the rate of morphologic 
leukemia-free state (MLFS) 
 
 
Study Design: 
This is an open label study to assess the safety and efficacy of CPX -351 as first intensive 
therapy in elderly (age >60 years) patients with AML with companion cognitive function 
testing to determine whether this contributes to outcome in these patients. Patients may 
have received prior AML treatment with non -intensive regimens, e.g. hypomethylating 
agents, low -dose cytarabine, or lenolidomide, bu t may not have received intensive AML 
treatment with anthracyclines and/or infusional cy tarabine prior to enrollment on this trial.  
The cohort will include 30 patients treated with single-agent CPX- 351. These patients will 
be assessed for efficacy and saf ety. Quality of life will be assessed using the FACT- LEU 
in all patients.  Cognitive function will be assessed using the Blessed Orientation -Memory-
Concentration Test and the Montreal Cognitive Assessment.  
 
Study enrollment is expected to be completed within approximately 2 years.   
Sample Size: 
30 patients 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 4 of 50  Study Drugs: 
CPX -351 (cytarabine:daunorubicin) Liposome Injection is a liposomal formulation of a 
fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of a 7:2:1 molar ratio of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol.  
 
 
CPX -351 is provided as a sterile, pyrogen- free, purple, lyophilized product in 50 mL glass, 
single -use vials.  Each 50 mL vial after reconstitution contains 20 mL of CPX- 351 (5 
units/mL). Each unit (u) contains 1.0 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5 ˚ ± 3
oC. 
 
 
Efficacy Variables & Analysis: 
 
x To assess the suitability of CPX 351 in older patients with AML and the 
relationship of cognitive function to outcome 
x Response rate (CR, CRp, CRi, and CR+CRp+CRi), (morphologic, cytogenetic and 
molecular response) 
x Response duration (relapse-free survival) 
x EFS 
x Evaluation of QOL of CPX treated patients 
x Evaluation of relationship of cognitive function to outcome in treated patients  
 
 
 
Safety Variables & Analysis:  
Patients will be monitored for all clinical adve rse events as well as laboratory evaluations. 
x Induction Mortality:  assessed at Day 30 and 60 ; therapies may be changed after 30 
days.  
x Serious Adverse Events 
x Adverse Events: Grades 1-5 and Grades 3-5 
x Laboratory Evaluations 
o Routine hematology (CBC+diff+Platelet count) and chemistry (with LDH) 
o Time to hematologic recovery and proportion with prolonged cytopenias ( ≥ 
56 days) 
x Cardiac Evaluations 
o Cardiac AEs: Grades 1-5 and Grades 3-5 
o ECG changes (pre-dose for each course, and at the end of each course ) 
o LVEF changes (pre and post treatment)  
 
Other Variables & Analysis: 
Quality of Life Assessment:   FACT- Leu will be used to assess patients at the start of 
treatment and one month after treatment completion.   
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 5 of 50  Cognitive Assessment:  The Blessed Orientation-Memory-Concentration Test and the 
Montreal Cognitive Assessment Mini will be administered at the start of treatment and one 
month after completion of therapy.   
Cardiac Assessments : All ECG and ECHO/cardiac MRI assessments will be obtained and 
read locally for patient care.  
 
 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 6 of 50  ABBREVIATIONS 
7+3 Seven days of continuous infusion of cytarabine at 100 mg/m2/day and three 
days of daunorubicin at 60 mg/m2/day 
5+2 Five days of continuous infusion of cytarabine at 100 mg/m2/day and 2 days 
of daunorubicin at 60 mg/m2/day 
ADR  Adverse Drug Reaction AE  Adverse Event AHD  Antecedent Hematologic Disorders ALL  Acute Lymphocytic Leukemia ALT  Alanine Transaminase (SGPT) AML  Acute Myeloid Leukemia ANC  Absolute Neutrophil Count Ara-U  Arabinosyluracil 
ASCO  American Society of Clinical Oncology 
AST  Aspartate Transaminase (SGOT) ATPase Adenosine triphosphatase AUC  Area under the plasma concentration-time curve BID  Twice daily BSA  Body Surface Area BUN  Blood Urea Nitrogen C  Celsius Cmax  Maximum plasma concentration CL  Clearance CNS  Central nervous system CPX-351 CPX-351 (cytarabine:daunorubicin) Liposome Injection CR  Complete Remission 
CRi  Complete Remission with incomplete hematologic recovery 
CRp  Complete remission with incomplete platelet recovery CRF  Case Report Form CMMoL Chronic Myelomonocytic Leukemia CTCAE Common Terminology Criteria for Adverse Events d  day DEHP  di(2-ethylhexyl)phthalate dL  deciliter DSMB  Data and Safety Monitoring Board DSPG  Distearoylphosphatidylglycerol DSPC  Distearoylphosphatidylcholine EC  Ethics Committee 
ECG  Electrocardiogram 
ECOG  Eastern Cooperative Oncology Group EFS  Event-free Survival ELN  European LeukemiaNet EOI  End of Infusion FDA  Food and Drug Administration FISH  Fluorescence in situ Hybridization 
g  gram(s) 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 7 of 50  GCP  Good Clinical Practice 
HCl  Hydrogen Chloride 
HIPAA Health Information Protection and Portability Act HIV  Human Immunodeficiency Virus HMA  Hypomethylating Agent HOVON Hemato-Oncologie voor Volwassenen Nederland HP  High Purity HSCT   Hematopoietic Stem Cell Transplantation ICF  Informed Consent Form ICH  International Committee on Harmonization ITT  Intent-to-treat IRB/EC  Institutional Review Board/Ethics Committee iv, IV  intravenous 
K-M  Kaplan-Meier 
L  liter LDH  Lactate Dehydrogenase LVEF  Left ventricular ejection fraction m
2  square meters 
MDR  Multi-drug Resistance MDS  myelodysplastic syndrome MedDRA Medical Dictionary for Regulatory Activities mg  milligram(s) mL  milliliter(s) MLL  Mixed Lineage Leukemia MPN  Myeloproliferative neoplasm MLS  Morphologic Leukemia-free State 
MRU  Medical Resource Usage 
MTD  Maximum Tolerated Dose MUGA Multiple Gated Acquisition scan mw  molecular weight N  Number, Population NF  National Formulary OS  Overall Survival PD  Persistent Disease PhEur  European Pharmacopoeia PHI  Protected Health Information PK  Pharmacokinetics PS  Performance Status 
q.s.  quantum sufficiat 
RBC  Red blood cells SAE  Serious Adverse Event SD  Standard deviation sAML  Secondary AML T
1/2  Half-life 
t-AML  Therapy-related AML 
Tmax  Time of occurrence of Cmax 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 8 of 50  u  Units 
μL  Microliter 
ULN  Upper Limits of Normal USP  United States Pharmacopeia V  Volume WHO  World Health Organization  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 9 of 50  TABLE OF CONTENTS 
1 General Information .....................................................................................................11 
2 Background Information ..............................................................................................11 
2.1 Acute Myeloid Leukemia in the Elderly and its Treatment ..................................11 
2.2 CombiPlex Technology and CPX-351 ...............................................................11 
2.3 CPX-351 Product Label ........................................................................................12 2.4 Rationale for CPX-351 use in Patients suitable for non-intensive therapy ..........12 2.5 Rationale for Assessment of Non-Hematologic Factors that Influence Outcome 
in Older AML Patients ........................................................................................14 
3 Study Objectives and Rationale ...................................................................................16 
3.1 Primary Objectives................................................................................................16 3.2 Secondary Objectives............................................................................................16 
4 Study Design ................................................................................................................ 16 
4.1 Patient Recruitment ...............................................................................................16 
4.2 Patient Sample Size...............................................................................................17 4.3 Induction ...............................................................................................................17  
4.4 Repeat of Induction ...............................................................................................17 4.5 Consolidation Therapy ..........................................................................................17 4.6 Follow-up Phase....................................................................................................18 4.7 Study Modification/Discontinuation .....................................................................18 
5 Selection and Withdrawal of Patients ..........................................................................18 
5.1 Study Population ...................................................................................................18 5.2 Withdrawal of Patients ..........................................................................................20 
6 Treatment of Patients ...................................................................................................20 
6.1 Pre-Treatment Evaluations....................................................................................20 6.2 Evaluation during Treatment Phase ......................................................................22 
6.3 Early Termination or End of Treatment Phase .....................................................23 
6.4 Evaluation during Follow-up Phase ......................................................................24 
7 Drug Administration ....................................................................................................24 
7.1 Drug Preparation and Administration ...................................................................25 7.2 Drug Accountability..............................................................................................26 7.3 Dose Reductions and Delays ................................................................................26 7.4 Concomitant Therapy............................................................................................27 7.5 Duration of Protocol Treatment ............................................................................28 
8 Assessment of Efficacy ................................................................................................28 
8.1 Efficacy Population ...............................................................................................28 8.2 Overall Survival ....................................................................................................28 8.3 Event-free Survival ...............................................................................................28 
8.4 Response Assessment Criteria ..............................................................................29 
8.5 Remission Duration ..............................................................................................30 8.6 Morphologic Leukemia-free State ........................................................................30 8.7 Stem Cell Transplant.............................................................................................30 
9 Assessment of Safety ...................................................................................................30 
9.1 Safety Population ..................................................................................................30 9.2 Adverse Events .....................................................................................................30 
9.3 Cardiac Toxicity Monitoring ................................................................................33 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 10 of 50  9.4 Laboratory Data ....................................................................................................32 
10 Other Evaluations....................................................................................................33 
11 Statistical Considerations ...........................................................................................34 
11.1 Primary and Secondary Endpoints ......................................................................35 11.2 Sample Size and Power Justification for Primary Endpoint ...............................35 11.3 Analysis Populations ...........................................................................................36 11.4 Analysis of Primary Endpoints ...........................................................................36 11.5 Analysis of Secondary Endpoints .......................................................................36 11.6 Safety Analysis ...................................................................................................36 
12 Administrative, Regulatory and Ethical Issues ..........................................................36 
12.1 Direct Access to Source Documents ...................................................................37 12.2 Study Monitoring and Quality Inspections/Audits .............................................38 12.3 Ethics...................................................................................................................3 8 
12.4 Adherence to the Protocol ...................................................................................38 
12.5 Protocol Revisions ..............................................................................................39 12.6 Retention of Patient Records and Study Files.....................................................39 12.7 Patient Confidentiality ........................................................................................39 12.8 Informed Consent................................................................................................40 12.9 Publication Policy ...............................................................................................41 
13 References ................................................................................................................. .42 
14 APPENDIX 1: Patient Evaluation Flow Sheet – Treatment Phase ...........................44 
15 APPENDIX 2: Patient Evaluation Flow Sheet –Follow-up ......................................45 
16 APPENDIX 3: Performance Status – ECOG.............................................................46 
17 APPENDIX 4: Common Terminology Criteria for Adverse Events V4.0 (CTCAE) ....................................................................................................................... .....47 
18 APPENDIX 5:  Elements of the HIPAA Privacy Rule Authorization ......................48 
19 APPENDIX 6:  Declaration of Helsinki ....................................................................49 
20 APPENDIX 7: Anthracyclines Equivalents Guidelines ............................................50 
 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 11 of 50  
 1 General Information 
This document is a protocol for a human research study. This study is to be conducted 
according to United States and international standards of Good Clinical Practice (FDA Title 21 parts 11, 50, 54, 56, 312, International Conference on Harmonization and the Declaration of Helsinki), applicable government regulations and Institutional research policies and procedures.  
2 Background Information 
2.1 Acute Myeloid Leukemia in the Elderly and its Treatment 
Acute Myeloid Leukemia in older patients is a poor prognosis disease.  While progress in 
supportive care, such as better antibiotic and antifungal therapy, have improved outcomes 
for younger persons with this disease, the overall survival of older patients has not changed 
through the years.  The reasons for the poorer prognosis of elderly patients are multifocal and include disease biology, comorbid illness, geriatric syndromes and social factors. Intensive treatment and consolidation chemotherapy can be difficult to administer to an older population. The intensiveness of treatment can be difficult to tolerate in older patients with other comorbid illnesses and geriatric syndromes. Physicians may modify doses to standard regimens to decrease presumed toxicities and inadvertently decrease the efficacy of treatment.   Once patients have recovered from induction chemotherapy, they may be too weak to withstand subsequent cycles of consolidation therapy and never achieve a deep, MRD negative, response to treatment and a durable response to therapy.    
2.2 CombiPlex
 Technology and CPX-351 
Combination chemotherapy regimens have traditionally been designed empirically on the 
basis of tolerability.  However, in vitro, where the ratio of drugs used in combination can be controlled, it has been demonstrated that drug combinations providing synergy at one ratio may be simply additive or even antagonistic at other ratios.
15  When individual free 
drugs are administered, each agent is handled differently by the body, resulting in varying distribution of the individual drugs to tumor si tes which can result in drug ratios that are 
suboptimal or ineffective.  Jazz’s  technology is based on the findings that in vitro 
synergistic activity of antineoplastic drugs depends on specific drug ratios and that the in vivo activity of a combination depends on maintaining the synergistic ratio.  In this way, the development of a particular chemotherapeutic regimen can be based on the most efficacious ratio rather than empirically based on toxicity.  
The development of CPX-351 (cytarabine:daunorubicin) Liposome Injection was based on 
1) defining a synergistic ratio of the two active moieties, cytarabine and daunorubicin, using cell-based screening assays and 2) designing a liposomal drug carrier to maintain this ratio after intravenous administration.  This ratio was not based on the empirically-derived, toxicity-guided regimens currently used for cytarabine and anthracyclines.  CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs 
cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 12 of 50  
 ratio.  The liposome membrane is composed of distearoylphosphatidylcholine, 
distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.  These liposomes 
have a nominal diameter of approximately 100nm and are suspended in sucrose.  Sterilization is achieved by filtration through a 0.22 μm filter. 
 CPX-351 is provided as a sterile, pyrogen-free lyophilized formulation in 50 mL glass, single-use vials.  Each vial contains 100 units of CPX-351 where each unit contains 1.0 mg cytarabine and 0.44 mg daunorubicin base in liposomes.  The lyophilized cake is reconstituted with sterile water for injection to obtain a homogeneous dispersion at 5 units/mL.  The composition of the formulation after reconstitution is listed in Table 1 below. 
 
Table 1:  Quantitative Composition  
 
Component mw Amount per 
Vial Amount 
per unit 
Cytarabine, USP/PhEur 243 100 mg 1.0 mg 
Daunorubicin HCl USP/ PhEur (reported as the free base) 528 44 mg 0.44 mg 
Distearoylphosphatidylcholine 790 454 mg 4.5 mg 
Distearoylphosphatidylglycerol 801 132 mg 1.3 mg 
Cholesterol, HP 387 32 mg 0.3 mg 
Copper gluconate, USP 454 92 mg 0.9 mg 
Triethanolamine, NF 149 7 mg 0.07 mg 
Sucrose, NF 342 2054 mg 20.54 mg 
 
2.3 CPX-351 Product Label 
CPX-351 (cytarabine:daunorubicin) LIPOSOME FOR INJECTION  100 units/Vial 
Each unit  contains 1.0 mg (±10%) Cytarabine and 0.44 mg  (±10%) Daunorubicin (base) in liposomes 
containing DSPC, DSPG and cholesterol.  Also contai ns copper as copper gluconate, triethanolamine and 
sucrose.  
Store refrigerated at 5 qqC (r3qC) in an upright position. 
FRAGILE: Do not drop 
Caution: New Drug – Limited by Federal Law to Investigational Use 
Manufactured for  
Jazz Pharmaceuticals, Inc., 200 PrincetonSouth Corporate Center 
Ewing, NJ 08628  
 
Lot #______________   Expiration Date:_________________ 
 
 
2.4 Rationale for CPX-351 use in Patients suitable for non-intensive therapy 
Three clinical studies have been completed with CPX-351 and a detailed presentation is 
available in the Investigator’s Brochure.  A brief summary of observations pertinent to treatment of AML patients, particularly those with co-morbidities and patients whose age tends of limit treatment to non-intensive regimens is discussed below.    The rationale for using CPX-351 to treat older patients thought to be unsuitable for 
treatment with intensive chemotherapy is roo ted in the characteristics of AML in older 
patients, the pharmacology and mechanism of CPX-351 action, and clinical observations 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 13 of 50  
 of the dose-response and safety of CPX-351.  It is well known that both the incidence of 
AML and the risk of AML resistance to chemotherapy increase in an age related manner.   Younger patients, particularly those younger than 45 years of age, have higher response rates, lower rates of primary refractory disease, and longer survival than patients over the age of 70.  This is associated with an age related rising risk of adverse cytogenetics and multidrug resistance phenotype.  CPX-351 packages cytarabine and daunorubicin within 
liposomes at a 5:1 molar ratio, found in vitro  to maximize drug synergy and minimize 
antagonism.   CPX-351 liposomes are stable and persist in the plasma for extended periods 
of time leading to cytarabine and daunorubicin half-lives of approximately 24 hours.  This result suggests that CPX-351 may be effective for both in rapidly and slowly cycling leukemias.  Exposure of leukemia cells from cell lines and circulating blast cells from patients demonstrate direct entry of CPX-351 liposomes and subsequent intracytoplasmic release of drug.  These observations suggest that effective treatment may be possible even 
in patients with multidrug resistance phenotype due to increased P-glycoprotein 
expression.  Clinical observations of CPX-351 safety and efficacy come almost exclusively from patients considered fit for intensive chemotherapy and indicate a safety profile that is very similar to that of 7+3 chemotherapy except for more prolonged myelosuppression.  In the clinic the dose-toxicity/response curve appears to be shallow with most of the grade 3/4 adverse events associated with prolonged myelosuppression rather than severe non-hematologic toxic events.    Taken together these findings suggest that treatment at the MTD (100 units/m
2/dose on day 
1, 3, and 5) is likely to be feasible, even in patients of advanced age and with some co-morbidities because the toxicities of treatment are mostly confined to myelosuppression and because supportive care with anti-infective prophylaxis is effective.  It is thought that 
full dose treatment is likely to maximize the probability of response and that response is 
possible even in patient populations enriched for adverse cytogenetics and multi-drug resistance phenotype.  The mode of action of CPX-351 should enable rapid clearance of leukemia from the peripheral blood and bone marrow with most patients achieving complete response after one induction course of treatment with recovery from neutropenia usually within 5-7 weeks.   
 
Treating an AML patient population usually considered suitable for non-intensive regimens with CPX-351 is not without risk.  This patient population is expected to be older with some baseline comorbidities and cannot be expected to be as resilient as the fit older population treated in Phase II with CPX-351.  In that study induction mortality was assessed at Day 30 and 60 and a lower rate of early mortality was observed for CPX-351 treated patients (4/85, 4.7% vs. 6/41, 14.6% at 60 days, p=0.053).  This result is the best 
evidence that CPX-351 treatment at full dose is likely to be acceptably safe and suggests 
that rapid clearance of leukemia due to full dose treatment may assist in reducing the contribution of leukemia to the early death rate.  The greater myelosuppression and more prolonged neutropenia following CPX-351 treatment was associated with a higher frequency of febrile neutropenia (63.5% vs. 51.2%), 
grade 3 and 4 infections (e.g. bacteremia (42.4% vs. 22%)), and bleeding events (e.g. 
epistaxis (36.5% vs. 19.5%)).  In spite of this the lower mortality rate at 30 and 60 days 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 14 of 50  
 indicates that CPX-351 was safe and strongly suggests that anti-infection prophylaxis was 
effective in preventing infection-related deaths in spite of risks of myelosuppression.   Most recently, a phase 3 trial comparing CPX-351 to standard induction chemotherapy with daunorubicin and cytarabine in older patients aged 60-75 with high risk AML was completed.  The Phase 3 trial compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3.  The median overall survival for patients treated with CPX-351 in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of CPX-351. The hazard ratio (HR) was 0.69 (p=0.005) which represents a 31% reduction in the risk of death versus 7+3. The percentage of patients alive 12 months after randomization was 41.5% on the VYXEOS arm compared to 27.6% on 
the 7+3 arm. The percentage of patients alive 24 months after randomization was 31.1% 
on the CPX-351 arm compared to 12.3% on the 7+3 arm.   Event-free survival was also statistically significant in favor of CPX-351. The HR was 0.74 (p-value=0.021). The median event-free survival was 2.53 months in the CPX-351 arm compared to 1.31 months in the 7+3 arm.   
CPX-351 also demonstrated a statistically significant improvement in induction response 
rate (CR+CRi of 47.7% versus 33.3%; p=0.016) and this significance was maintained for 
the analysis of CR alone (CR of 37.3% versus 25.6%, p=0.040).  
 
Thirty-four percent of CPX-351 treated patients received a stem cell transplant (SCT) 
compared to 25% of 7+3 treated patients. In a landmark survival analysis of patients 
receiving a SCT, CPX-351 patients had significantly improved survival post-transplant 
(HR was 0.46 (p-value=0.0046)). The median overall survival had not been reached in the 
CPX-351 treated patients compared to 10.25 months in the 7+3 treated patients. 
 
Thirty-day and sixty-day all-cause mortality favored CPX-351. Thirty-day mortality was 
5.9% compared to 10.6% and sixty-day mortality was 13.7% versus 21.2%. 
Grade 3-5 non-hematologic and hematologic adverse events were similar between the 
VYXEOS and 7+3 arms. 
 
On the basis of the phase 3 trial data, CPX 351 was approved by the FDA for treatment of 
older patients aged 60-75 with prior myeloid hematologic disease. 
 
 
2.5 Rationale for Assessment of Non-Hematologic Factors that Influence 
Outcome in Older AML Patients 
 
Treatment outcome of older AML patients is closely linked to the age of the patient.  
Data from the Swedish Acute Leukemia Registry confirms that patient outcome worsens 
with increasing age.  Presumably, the older th e age of the patient, the more complicated 
the disease: the biology of the disease is more severe in the elderly and patients have more 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 15 of 50  
 difficulty tolerating the consequences of chemotherapy treatment. Determining the fitness 
of an older patient for chemotherapy treatment can be quite challenging. The biologic age of an older person may differ significantly from the numeric age: there can tremendous variability in the fitness and function of older people at any given chronologic age after age 60. There is no scientific algorithm to assess the actual biologic age of an older adult. Adverse disease related prognostic factors are more easily measured. Older patients are much more likely to have adverse cytogenetics and unfavorable molecular mutations.  Older patients have a higher rate of multi-drug resistant phenotypes and antecedent hematologic disorders. The patient-specific prognostic factors such as severity of comorbid illness, fitness and social support are more difficult to quantify.  Many older patients have comorbid illnesses that may or may not be apparent at the time of leukemia diagnosis.  Drug metabolism is different in older patients and is influenced by diminished renal and hepatic function that also may not be clinically apparent at the time of diagnosis.  The 
elderly have deficits in immune function that make the tolerance of infections less robust. 
Patients often have diminished physical conditioning and endurance that may not be visible on routine physical examination.  In addition, numerous psychosocial factors influence the outcome of older adults with AML including cognitive decline, social isolation, and lack of a caretaker.  The patient-related prognostic factors are more difficult to measure and their significance may not emerge until after treatment for their leukemia has already been given.   
Through using the Comprehensive Geriatric Assessment (CGA) to evaluate elderly 
patients with AML, studies have shown that there appears to be a relationship between cognitive function and outcome in older patients treated for AML.  This study will explore this relationship further by implementing cognitive testing to determine this relationship in patients treated with CPX 351. Klepin et al. conducted a study of 74 older AML patients 
treated with intensive daunorubicin/cytarabine induction and used the CGA to assess 
patients for chemotherapy fitness. This study demonstrated that impaired cognition (defined as <77 by the Modified Mini-Mental State Exam) and impaired objective physical function (defined as an SPPB<9) predicted a w orse overall survival in older adults with 
AML.   Ritchie et al. (unpublished data) completed an analysis using the CGA to predict overall survival in patients aged 60 or older receiving induction therapy for AML with 
either standard induction with daunorubicin and cytarabine or low intensity induction with 
decitabine. One hundred and twenty-six patients were enrolled.  Cognitive function as measured by the Blessed Orientation-Memory-Concentration Test. Patients with impaired cognitive function had worse overall survival in univariate analysis but in multivariate analysis this variable lost significance. A small percentage of patients with normal cognitive function on the Blessed Test were given the Montreal Cognitive Assessment and were impaired by measurement on this test.  The Blessed may not have been sensitive 
enough to stratify the cognitive deficits in the population tested.  Alternatively, the level of 
family and social support given to these patients may be more important than cognitive function in the survival of older patients with AML.  Given that Klepin’s analysis of patients suggested that cognitive function is important to the survival of older patients with AML and that more sensitive testing may be needed to determine the level of cognitive impairment in this population, cognitive testing using both the Blessed and the MOCA will 
be used in this study to determine whether this is an important factor in the survival of older 
patients with AML.  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 16 of 50  
 3 Study Objectives and Rationale 
3.1 Primary Objectives 
x To assess the feasibility of CPX-351 as first intensive therapy in elderly (age ≥60 
years) patients with AML based on safety and efficacy and to evaluate cognitive function in these patients and its relationship to outcome.  CPX-351 alone will be declared feasible if one or two induction courses (3 doses or 5 doses) can be delivered to patients with acceptable 30-day mortality. The primary efficacy endpoint will be overall survival (OS).  The primary safety endpoint will be early mortality defined as 30-day mortality.  
 
 
3.2 Secondary Objectives 
x To assess efficacy by response (CR, CRp, CRi, and CR + CRp + CRi) rate and  
duration and Event Free Survival (EFS) 
 
x To assess safety by 30-day mortality, serious adverse events (SAE) and adverse event 
frequency and severity   
x To assess QOL using FACT-LEU  
 
x To assess the relationship of cognitive function to outcome using the Blessed 
Orientation-Memory-Concentration Test and the Montreal Cognitive Assessment  
 
x To confirm the safety and practicality of CPX-351 as consolidation therapy 
 
x To supplement efficacy assessment by determining the rate of morphologic 
leukemia-free state (MLFS) 
 
4 Study Design 
This is an open label study to assess the suitability of CPX-351 as first intensive therapy in 
elderly (age ≥60 years) patients with AML. Patients may have received prior AML 
treatment with non-intensive regimens, e.g. hypomethylating agents, low dose Ara C or lenolidomide, but may not have received in tensive AML treatment with anthracyclines 
and/or cytarabine prior to enrollment on this trial.  The outcome of elderly patients following intensive treatment with CPX-351 will be measured by clinical endpoints for efficacy and safety and by biological/functional response.    
4.1 Patient Recruitment 
All patients will be screened for study suitability by a principal investigator or sub-
investigator prior to entry on the study.  An explanation of the study and discussion of the expected risks and benefits will be fully discussed with patients prior to the screening process in order for the patient to provide a voluntary written informed consent.  Only eligible and consenting patients will be entered into the study. 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 17 of 50  
 4.2 Patient Sample Size 
Early mortality (30 day mortality) in newly diagnosed fit older (age > 60 years) patients 
with AML initially treated with standard induction therapy with daunorubicin and 
cytarabine is approximately 20%.  Older patients with AML who are less fit, particularly those initially treated with non-intensive regimens, are expected to have 60-day mortality of approximately 40%.  After 15 patients have been treated and followed for 30 days or more, early mortality will be assessed.  If 30-day mortality exceeds 20% (>3 of the initial 
15 patients), all further accrual will stop .  Subsequent enrollment after the first 15 subjects 
should ideally resume after the safety analysis is complete, however recognizing the acute 
nature of AML, it might not be possible to deny treatment to subjects in screening for ethical reasons sufficiently long to evaluate safety or efficacy. In other words, if the 30-day mortality for the preceding patients is less than 20%, study accrual will continue during 
the DSMB’s safety analysis.  
  In the event that more than 15 subjects have enrolled before the safety analysis, only the first 15 subjects dosed will be informative for determining need for dose reduction.  Study enrollment will be completed within approximately 2 years.    
4.3 Induction 
Following registration, patients will be monitored closely for response and safety. 
Depending on the type and extent of response as well as toxicity, the patient may continue on to consolidation therapy, receive a second induction, or be discontinued from the Treatment Phase and monitored in the Follow-up Phase.  
Dosing for first induction: CPX-351 alone 
x CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5  
 
4.4 Repeat of Induction 
Patients achieving aplasia/hypoplasia (<5% blast count) will not receive second inductions.  
Patients with reduced tumor burden and evidence of persistent leukemia who remain fit for 
additional intensive chemotherapy can be given second inductions up to 60 days (measured 
from day 1 of chemotherapy treatment) after the first induction treatment date.  
 Patients unable to achieve a response (CR, CRp, or CRi) after up to 2 inductions are discontinued from further treatment and followed for survival.  
Dosing for second induction: 
x CPX-351 at 100 u/m2 will be administered on days 1 and 3  
 
4.5 Consolidation Therapy 
 
Only patients with confirmed response (CR or CRp or CRi) and who remain fit for 
additional chemotherapy are eligible for chemotherapy consolidation.  Investigators may 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 18 of 50  
 use post remission therapy of their choice or they may choose to use CPX-351.  Before 
consolidation treatment can begin, patients need a repeat echocardiogram and labs to evaluate renal and liver function and must fulfill eligibility criteria initiation of treatment.   
For patients given CPX-351 post remission therapy: prior to starting consolidation, LVEF must be documented to be ≥50% and patients must have recovered to ANC >500/ μL and 
platelets >50,000/ μL within 56 days after last dose of CPX-351.  A second consolidation 
cycle is permitted provided the first consolidation course was well tolerated and repeat echocardiogram shows an LVEF > 50% and ANC and platelets have recovered within 56 days of the start of the last consolidation cycle.  Up to 2 consolidation courses are permitted.  Scheduling and dose of consolidation treatment may be adjusted depending on degree and rate of patient recovery.  
 Dosing for consolidation: 
x CPX-351 at 65 u/m2 will be administered on days 1 and 3  
 
4.6 Follow-up Phase 
Patients will be followed at monthly intervals or more frequently depending on clinical 
circumstances until start of the next salvage treatment, death or for 1 year from date of enrollment. Patients alive and in remission after 1 year will be followed annually or more frequently depending on clinical circumstances for up to 5 years from enrollment.  For EFS evaluation, events include: documentation of persistent AML after induction, relapse after achievement of CR/CRp/ CRi, or death.  Bone marrow assessments will be performed at any time during follow up when recurrent cytopenias raise the suspicion of AML relapse.  After documentation of persistent leukemia or relapse, follow-up for OS will continue. At the start of HSCT or non-protocol AML treatment of any sort or 30-days following the last 
dose, whichever occurs first, AE data collection will stop.   
 
4.7 Study Modification/Discontinuation 
Any modifications to the study will be documented in a revised protocol with a new 
assigned version.  The revised protocol will have an appendix which will detail the revisions to the document. 
 
5 Selection and Withdrawal of Patients 
5.1 Study Population 
5.1.1 Inclusion criteria 
5.1.1.1  Ability to understand and voluntarily give informed consent 
5.1.1.2  Age≥60 years at the time of study treatment  
5.1.1.3  Pathological diagnosis of AML according to WHO criteria (with >20% blasts in 
the peripheral blood or bone marrow) including: 
5.1.1.4  De novo AML with normal karyotype or adverse karyotypes (including patients 
with karyotypic abnormalities characteristic of MDS) 
5.1.1.5  Secondary AML: transformed from prior MDS or MPN, confirmed by bone 
marrow documentation of prior antecedent hematologic disorder 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 19 of 50  
 5.1.1.6  Therapy-related AML: t-AML, requires documented history of prior cytotoxic 
therapy or ionizing radiotherapy for an unrelated disease 
5.1.1.7  Performance status >50% KPS, ECOG 0-2 
5.1.1.8  Laboratory values fulfilling the following: 
5.1.1.9  Serum creatinine < 2.5 mg/dL 
5.1.1.10  Serum total bilirubin < 2.5 mg/dL,  
5.1.1.11  Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN  
5.1.1.12  Patients with elevated liver enzymes and serum creatinine values secondary to 
AML are eligible after discussion with PI 
5.1.1.13  Cardiac ej ection fraction ≥ 50% by echocardiography , MUGA, or Cardiac MRI 
5.1.1.14  Patients with history of second malignancies in remission may be eligible if there 
is clinical evidence of disease stability off cytotoxic chemotherapy, documented 
by imaging, tumor marker studies, etc., at screening. Patients maintained on long-term non-chemotherapy treatment, e.g., hormonal therapy, are eligible. 
5.1.2 Exclusion Criteria 
5.1.2.1  Acute promyelocytic leukemia [t(15;17)] 
5.1.2.2  Clinical or morphologic evidence of active CNS leukemia 
5.1.2.3  Prior intensive chemotherapy for AML with anthracycline/cytarabine-based 
regimens and/ or prior HSCT. Patients may have been treated with commercially available or investigational hypomethylating agents (e.g. decitabine, azacitidine, SGI-110), lenalidomide, or low-dose cytarabine (not to exceed 20 mg/m2 daily for 14 days for ≤ 6 cycles)  
5.1.2.4  Prior treatment including HMA, systemic chemotherapy, surgery, or radiation 
therapy must have been completed at least 7 days before start of study treatment or after discussion with PI.  Treatment with investigational agents must have been completed at least 14 days prior to study drug treatment.  Hydroxyurea is permitted for control of blood counts before the start of study treatment. Toxicities associated with prior therapies must have recovered to grade 1 or less prior to start of study treatment. 
5.1.2.5  Patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 
daunorubicin (or equivalent). 
5.1.2.6  Any serious medical condition, laboratory abnormality or psychiatric illness that 
would prevent obtaining informed consent 
5.1.2.7  Patients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic 
heart disease, significant valvular dysfunction, hypertensive heart disease, and 
congestive heart failure) resulting in heart failure by New York Heart Association Criteria (Class III or IV staging) 
5.1.2.8  Active or uncontrolled infection. Patients with an infection receiving treatment 
(antibiotic, antifungal or antiviral trea tment) may be entered into the study but 
must be afebrile and hemodynamic ally stable for ≥72 hrs.  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 20 of 50  
 5.1.2.9  Patients with current or recent evidence of invasive fungal infection (blood or 
tissue culture); patients with recent fungal infection must have a subsequent negative cultures to be eligible  
5.1.2.10  Known HIV (new testing not required) or evidence of active hepatitis B or C 
infection (with rising transaminase values) 
5.1.2.11  Hypersensitivity to cytarabine, daunorubicin or liposomal products 
5.1.2.12  History of Wilson’s disease or other copper -metabolism disorder 
5.1.2.13  History of prior bone marrow or solid organ transplantation 
 
5.2 Withdrawal of Patients 
Patients will be discontinued from the Treatment Phase and enter the Follow-up Phase for 
assessment of efficacy endpoints under the following circumstances: 
x Completion of Treatment Phase  
x Persistent disease:  lack of a response to treatment  
x Relapsed disease:  re-appearance of disease following CR, CRp, or CRi  
x Unacceptable toxicity  
x Patient non-compliance with protocol  
x Administration of non-protocol chemotherapy  
x Concurrent illness which, in the judgment of the investigator, effects assessment of 
clinical status to a significant degree, and requires discontinuation of protocol therapy.
 
 Any adverse event that, in the judgement of the investigator, may cause severe or permanent harm if the study intervention is continued will result in subject discontinuation 
from the study.  Any treatment related grade 3 or higher non-hematological toxicity that 
does not resolve to grade 2 within 14 days of receiving treatment for the event will result in subject discontinuation from the study.  During any phase of the study, if a patient requests to stop treatment and/or follow-up, the patient will be discontinued and no further information will be collected.  The patient will be classified as withdrawal of consent.   
 
6 Treatment of Patients 
See APPENDIX 1: Patient Evaluation Flow Sheet 
 
6.1 Pre-Treatment Evaluations 
After providing informed consent, eligible patients are registered to the study.  
 The date of the first test or exam will be considered as the date of the screening visit. 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 21 of 50  
 Procedure  Evaluation Timing 
Informed Consent It should be personally signed and dated by 
the patient. The responsible investigator 
must also personally sign and date the 
document.  
A copy of the Informed Consent must be 
given to the patient.  
The patient’s study screening must be 
conspicuously noted in the source 
documentation. Informed consent should be 
obtained prior to initiation of 
screening procedures. If the 
period between ICF signature date and induction 1, day 1
 visit is ≥30 days the 
patient must sign another ICF.
 
 
Demography Date of birth, sex, race, ethnicity Within 14 days prior to  
Registration 
Medical History Complete medical history 
x Resolved conditions 
x Intermittent conditions 
x Concurrent illnesses 
x Previous surgeries Within 14 days prior to 
registration  
Leukemia History Leukemia, MDS, and MPN History 
Prior chemotherapies  
Prior leukemia treatment Within 14 days prior to 
registration  
Physical Exam Objective review of body systems  
Height  
Weight  
BSA  
ECOG Performance Status Within 3 days prior to 
registration  
Vital Signs Heart rate 
Blood pressure  
Temperature  
Respiratory rate Within 3 days prior to 
registration  
Hematology Hemoglobin 
White Blood Count  
Platelets  
Differential Count Within 1 day prior to 
registration  
Biochemistry 
 BUN 
Creatinine  
Uric Acid  
Electrolytes (Sodium, Potassium, Chloride) 
Bilirubin  
Alkaline phosphatase  
AST or ALT  
LDH  
Protein  
Calcium  
Albumin  
Glucose Within 1 day prior to 
registration  
Urinalysis pH 
specific gravity  
glucose  
protein  
ketones  
blood Within 3 days prior to 
registration  
Questionnaires MOCA, Blessed, FACT-Leu Within 7 days prior to 
registration 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 22 of 50  
 Procedure  Evaluation Timing 
Bone Marrow 
Aspiration/Biopsy Morphology 
 Within 14 days prior to 
registration 
Diagnostic Imaging Chest X-ray or Chest CT 
 Within 28 days prior to 
registration 
Diagnostic Imaging Echocardiography, MUGA or cardiac MRI 
scan  Within 14 days prior to 
registration 
Electrocardiogram (ECG) ECG Within 14 days prior to 
registration  
Cytogenetics  
 Cytogenetics (performed locally) Within 3 months prior to 
registration 
Molecular Studies Central or local laboratory evaluation of 
CEBPA, FLT3, and NPM1 (either PB or BM) Within 3 months prior to 
registration  
 
 
6.2 Evaluation during Treatment Phase 
Inductions and consolidations are administered as courses.  A course consists of the 
administration of therapy with scheduled assessme nts to evaluate the response to treatment.  
The first induction may end before the completion of all evaluations if a second induction is necessary, (see Section 4.4).  Induction is completed when a patient has 
x A confirmed CR (see section 8.4)  
x A CRp or CRi (see section 8.4) and is to begin consolidation treatment before 
hematologic count recovery  
x Persistent/recurrent disease (PD/relapse)  
x Resp onse evaluation cannot be performed becau se of the patient’s condition and no 
further study treatment can or will be administered.  
 
Patients with a CR or CRi may receive up to 2 consolidation treatments.  
 
Procedure Evaluation Timing 
Physical Exam Objective review of body systems  
Weight  
BSA Days 14 and 42 
Vital Signs Heart rate 
Blood pressure  
Temperature  
Respiratory rate Days 14 and 42 
Hematology Hemoglobin 
White Blood Count  
Platelets  
Differential Count  Days 1, 3, 5, 7±3, 10±1, 14±2, then 
weekly (±2days) until whichever occurs last:
 
- Day 42  
- peripheral blood count recovery 
- removed from Treatment Phase 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 23 of 50  
 Procedure Evaluation Timing 
Biochemistry BUN 
Creatinine  
Uric Acid  
Electrolytes (Sodium, Potassium, 
Chloride)  
Bilirubin  
Alkaline phosphatase  
AST or ALT  
LDH  
Protein  
Calcium  
Albumin  
Glucose Days 1, 3, 5, 7±3, 10±1, 14±2, then 
weekly (±2days) until whichever occurs 
last: 
- Day 42  
- peripheral blood count recovery 
- removed from Treatment Phase 
 
 
 
    
Bone Marrow Evaluation Morphology 
 
 As needed to confirm response or 
determine antileukemic effect and need 
for second induction. 
Cytogenetics  
Molecular Studies  Cytogenetics  
Molecular Studies  Required in patients with a CR, CRp, or 
CRi with positive baseline findings (perform at the time of bone marrow assessment for CR
 or CRi). Optional in 
patients with normal baseline 
cytogenetics/molecular studies. 
Diagnostic Imaging Echocardiography, MUGA or 
cardiac MRI scan After the last induction and before each 
consolidation cycle.  
Questionnaires MOCA, Blessed, FACT-Leu Days 7±3, 42±3, Induction 2 Day 1(±3) 
Adverse Events/Toxicity CTCAE v.4 assessment Continual assessment starting from the 
first dose until 30 days after completion of the Treatment Period. 
Concomitant Medications  Continual assessment during Treatment 
Period.  
 
6.3 Early Termination or End of Treatment Phase 
Any patient that completes or discontinues tr eatment must have the following evaluations 
performed within 30 days after termination and prior to the initiation of any salvage therapy, if not performed within the last 30 days:  
Procedure Evaluation Timing 
Diagnostic Imaging Echocardiography, MUGA or 
cardiac MRI  Within 30 days after discontinuation if a 
study has not been performed since last 
treatment or before the initiation of any 
non-protocol treatment 
Electrocardiogram (ECG) ECG Within 30 days after discontinuation 
Adverse Events/Toxicity CTCAE v.4 assessment  Assess Adverse events that were 
ongoing at the time of discontinuation and record and report any new serious adverse events (up to 30 days after discontinuation) 
Response Assessment Best Response 
Reason for End of Treatment Within 30 days after discontinuation 
Questionnaires MOCA, Blessed, FACT-Leu Within 30 days after discontinuation 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 24 of 50  
  
6.4 Evaluation during Follow-up Phase 
The following evaluations are completed during the follow-up phase: 
Procedure Evaluation Timing 
Patient status report Survival status  
 Once monthly until 1 year from first 
treatment. After the first year record only 
the date of death or alive at Year 5 (Day 
1825).  
Relapse status 
New anti -leukemic therapies Once monthly until 1 year from first 
treatment. After the first year record only the date of relapse and any new leukemic therapies. 
Hematology Hemoglobin 
White Blood Count  
Platelets  
Differential Count Once monthly until 1 year from first 
treatment.  After the first year record only 
the date of relapse and any new leukemic 
therapies. 
Bone Marrow Evaluation Morphology 
 For patients in CR or CRi perform at any 
time that there is a suspicion of relapse. 
Following the first year of follow up, 
record relapse information, including any 
bone marrow evaluations.  Not required 
following relapse. 
Diagnostic Imaging Echocardiography, MUGA or 
cardiac MRI  If last treatment phase LVEF was reduced 
>10% from baseline and is less than 50% repeat every 3 months until LVEF returns to baseline ± 5% or until 1 year from first treatment. Persistent reductions in LVEF 
of >10% with nadir values below 50% 
documented at
 1 year are considered 
permanent sequelae.  
Biochemistry BUN 
Creatinine  
Electrolytes (Sodium, Potassium, 
Chloride)  
Bilirubin  
Alkaline phosphatase  
AST or ALT  
Protein  
Calcium  
Albumin  
Glucose Perform monthly only if abnormality(ies) 
persists at the end of the Treatment Phase.  
Perform until abnormality(ies) returns to baseline, until 1 year from first treatment 
or the initiation of new therapy and/or 
relapse. (whichever is earliest)
 
Adverse Events/Toxicity CTCAE v.4 assessment  Assess AEs that were ongoing at the time 
of discontinuation. Do NOT record any new AEs.  AEs that persist without 
evidence of recovery for >30 days are 
considered permanent sequelae and do 
not require further follow-up. 
 
7 Drug Administration 
The responsibility for treatment of patients rests with the individual investigator.  Protocol 
treatment must begin within 72 hours of registration. 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 25 of 50  
 First Induction: 
  
Agent Dose Route Duration Schedule 
CPX-351 100u/m2/day IV 90 minutes* Days 1, 3 and 5  
 
 Second Induction: 
Agent Dose Route Duration Schedule 
CPX-351 100u/m2/day IV 90 minutes* Days 1 and 3  
 
Consolidations (up to 2 are permitted): 
*Approximately 
 
Agent Dose Route Duration Schedule 
CPX-351 65u/m2/day IV 90 minutes* Days 1 and 3  
 
 
7.1 Drug Preparation and Administration 
7.1.1 CPX-351 
7.1.1.1  Drug Preparation 
The appropriate number of vials of CPX-351 (cytarabine:daunorubicin) Liposome 
Injection should be removed from the refrigerator prior to reconstitution.  Reconstitute with 19 mL of sterile water for injection using a 20 mL syringe. Do not heat CPX-351 (cytarabine:daunorubicin) Liposome Injection.  After reconstitution, invert vials gently 3-4 times and let rest for 15 minutes and repeat vial inversion prior to withdrawing drug for dilution.  The concentration of the reconstituted dispersion is 5 u/mL.  CPX-351 (cytarabine:daunorubicin) Liposome Injection should be diluted in approximately 500 mL 
of sodium chloride injection or dextrose injection. 
 The IV bags and infusion sets must be non-DEHP.  Aseptic technique must be strictly observed throughout the handling of CPX-351 (cytarabine:daunorubicin) Liposome Injection since no bacteriostatic agent or preservative is present.  The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection must be started within 4 hours of dilution.  Vials are for single use.  Unused material should be recorded as such and discarded according to institutional policies.  Procedures for proper handling and disposal of anticancer drugs should be implemented. 
 
7.1.1.2  Drug Administration 
The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed 
through a central venous catheter, using an infusion pump to ensure that the drug is infused 
over the specified time period.  Non-DEHP containing administration sets should be used.  Do not use an in-line filter.   CPX-351 should never be given by the intramuscular or 
subcutaneous route.  Administer CPX-351 over approximately 90 minutes via an infusion pump.  Flush the line to ensure administration of the full dose.  
The dosage (total units and u/m
2), start/stop time of the infusion, total volume infused, must 
be documented in the patient’s chart . 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 26 of 50  
  
(Reconstitution information to be obtained from pharmacy as well as infusional instruction)  
7.2 Drug Accountability 
The study pharmacist or designee must maintain records of the delivery of CPX-351 to the 
study site, the inventory at the site, the use by each patient, and the disposition of unused product. These records should include dates, quantities, lot numbers, expiration dates and patient identifications.  Institutions should ma intain records that document adequately that 
the patients were provided the doses specified by the protocol and reconcile all investigational product received from Jazz Pharmaceuticals.  Records of storage conditions (temperature logs) must be kept for the entire period that CPX-351 is maintained at the institution. 
 
7.3 Dose Reductions and Delays 
It is the intention of the study to treat every patient at full dose.  Dose delays or 
modifications will be recommended at the disc retion of the treating physician and PI. Doses 
may be delayed due to toxicities (for example hypersensitivity reactions).  Any doses missed or delayed due to toxicity may be administered as soon as the patient has recovered from the toxicity. Toxicities will be graded using the CTCAE Version 4.0. See APPENDIX 4: Common Terminology Criteria for Adverse Events V4.0 (CTCAE)).  Toxicities for cytarabine and daunorubicin are relatively well known, and are outlined in the product information for each of these drugs. Furthermore, dose reductions or protocol closure will be considered:   
1) If >2 of the first 5 patients or >3 of the fi rst 15 patients experience grade 4 toxicities, 
accrual will stop, the protocol reviewed, and dose modifications considered. If the incidence of grade 4 toxicity exceeds 20% of patients at any point after the first 15 patients have been treated, accrual will stop, the protocol will be reviewed, and dose modifications considered. 
  
2)  If 30-day mortality exceeds 20% (>3 of the initial 15 patients), all further accrual 
will stop.  Subsequent enrollment after the first 15 subjects should ideally resume 
after the safety analysis is complete, however recognizing the acute nature of AML, 
it might not be possible to deny treatment to subjects in screening for ethical reasons sufficiently long to evaluate safety or efficacy. In other words, if the 30-day mortality for the preceding patients is less than 20%, study accrual will continue 
during the DSMB’s safety analysis.  
 
In the event that more than 15 subjects have enrolled before the safety analysis, only the first 15 subjects dosed will be informative for determining need for dose reduction as outlined in section 4.2. 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 27 of 50  
 7.4 Concomitant Therapy 
7.4.1 Premedication 
7.4.1.1  CPX-351 
Nausea and vomiting: 
Patients may be premedicated for nausea and vomiting according to institutional standards. 
 Hypersensitivity/Infusion-related reactions: 
Patients will not be routinely premedicated for hypersensitivity or infusion-related reactions initially during the first infusion of the first treatment course.  If the patient develops a hypersensitivity reaction then he/she should be pre-medicated at all subsequent infusions.  
Suggested guidelines for management of hypersensitivity reactions: 
 
Mild symptoms (e.g., mild flushing, rash, pruritus): 
Stop infusion and supervise at bedside with monitoring of vital signs 
Reinitiate infusion slowly (halving the rate of infusion) +/- premedication  
Moderate symptoms (e.g. moderate rash, flushing, mild dyspnea, chest discomfort): 
Stop infusion and give IV diphenhydramine, 20-25 mg (or equivalent) and IV 
dexamethasone 10 mg. Do not reinitiate infusion.  Premedicate on re-treatment.  Retreat at same dose and rate.  
Severe/life-threatening symptoms (e.g. hypotension requiring vasopressor therapy, 
angioedema, respiratory distress requiring bronchodilation therapy, generalized 
urticaria): 
Stop infusion.  Administer IV diphenhydramine and dexamethasone as indicated above.  
Add epinephrine (adrenaline) or bronchodilators if indicated.  Do not reinitiate infusion.  Do not retreat. Report as a serious adverse event.  If hypersensitivity or infusion-related reactions become a clinically relevant toxicity, then 
premedication for hypersensitivity reactions will be instituted with drugs, doses and 
schedule according to each investigator’s preference.  Additionally, a decision may be made to prolong the infusion time to two hours or more.   Permitted therapy 
Patients may receive ongoing supportive and palliative care (e.g. pain control) as clinically indicated throughout the study.  Infection Prophylaxis:  Prophylactic use of antibiotics, antifungals, and antiviral drugs is 
highly recommended during the period of profound neutropenia until ANC returns to 500/μL or greater. The choice of medications will be according to institutional protocol. 
Use of anti-infective agents as prophylaxis and treatment must be documented on the case 
report forms. 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 28 of 50  
  
Growth Factor support: The use of growth factors will be according to institutional protocol 
and according to ASCO criteria.16 Use of growth factors must be documented on the case 
report forms.  Transfusion support:  The use of transfusion support (RBCs and platelets) will be according 
to institutional protocol.  Use of transfusion support must be documented on the case report forms.  
7.4.2 Therapy that is not permitted 
Other anti-cancer treatment and other investigational therapy(ies) are not permitted during 
the Treatment Phase.  In the event of persistent disease or relapse the patient may receive 
other anti-leukemic therapies and is followed for survival. 
 
7.5 Duration of Protocol Treatment 
Patients may continue on study provided they have not met the criteria for discontinuation 
of therapy (See Section 5.2).  Patients may receive up to 2 induction courses followed by up to 2 consolidation courses.  After the Treatment Phase, patients will be followed for up to 5 years.  
 
8 Assessment of Efficacy 
8.1 Efficacy Population 
All registered patients are evaluable for efficacy.  Patients that die on or before Day 7 will 
be replaced. 
 
8.2 Overall Survival  
Overall survival is measured from the date of registration to death from any cause. Patients 
not known to have died will be censored on the date they were last known to be alive. Patients will be followed for up to 5 years.     
8.3 Event-free Survival 
Event-free survival is defined as the time from study registration to the date of induction 
treatment failure (persistent disease), progressive disease (PD) or death from any cause, whichever comes first.  Patients alive and not known to have any of these events will be censored on the date of their last tumor assessment. 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 29 of 50  
 8.4 Response Assessment Criteria 
During the Treatment Phase patients will be assessed for response according to the 
following criteria1: 
Complete remission (CR)
a Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count 
>1.0 x 109/L (1000/ μL); platelet count > 100 x 109/L 
(100,000/ μL); independence from red cell transfusions  
CR with incomplete recovery (CRi)
b All CR criteria except for residual neutropenia (<1.0 x 10
9/L [1000/ μL]) or thrombocytopenia (<100 x 109/L 
[100,000/ μL]) 
Best Response See Section 8.4.1 
Treatment failure  
Persistent Disease (PD) 
 Failure to achieve CR or CRi; only includes patients 
surviving ≥7 days following completion of initial 
treatment, with evidence of persistent leukemia  (blasts in 
peripheral blood, extramedullary leukemia, or persistence in the bone marrow)  
Death in aplasia Deaths occurring ≥7 days following completion of initial 
treatment while cytopenic; with an aplastic or hypoplastic bone marrow obtained within 7 days of death, without evidence of persistent leukemia 
Death from 
indeterminate cause  Deaths occurring before completion of therapy, or <7 days 
following its completion; or deaths occurr ing ≥7 days 
following completion of initial therapy with no blasts in the blood, but no bone marrow examination available at 
recovery 
Relapsec Bone marrow blasts ≥5%; or reappearance of blasts in the 
blood after achievement of a CR or CRi; or development of extramedullary disease 
aBone marrow assessment REQUIRED to confirm CR. A ll criteria need to be fulfilled; marrow evaluation 
should be based on a count of 200 nucleated cells in an aspirate with spicules; if ambiguous, consider repeat 
exam after 5 to 7 days; flow cytometric evaluation ma y help to distinguish between persistent leukemia and 
regenerating normal marrow; a marrow biopsy should be performed in cases of dry tap, or if no spicules are obtained; no minimum duration of response required. 
bBone marrow assessment REQUIRED to confirm CRi. Some patients may not achieve complete 
hematologic recovery prior to initiatio n of consolidation.  CRi cannot be declared earlier than Day 35 to 
allow adequate time for documentation of peripheral bl ood recovery.  Consolidation may begin no earlier 
than 35 days after the last induction course. 
cIn cases with low blast percentages (5-10%), a repeat marrow should be performed to confirm relapse. 
Appearance of new dysplastic changes should be close ly monitored for emerging relapse. In a patient who 
has been recently treated, dysplasia or a transient incr ease in blasts may reflect a chemotherapy effect and 
recovery of hematopoiesis. 
 
A subject who is alive in a state of aplasia with no evidence of continued disease will be considered as having “no response.”  
 
The response of patients with no post-baseline bone marrow assessment will be entered as 
not done. 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 30 of 50  
  
8.4.1 Best Response 
Patients who complete the induction(s) with a response of CRp or CRi may be upgraded to 
CR during or after consolidation if the patient’s peripheral blood counts meet the criteria for CR (ANC>1000/ μL and Platelets >100,000/ μL).  To upgrade a response to CR after 
peripheral blood count recovery, a new bone marrow assessment must be performed within 
14 days of documented peripheral blood count recovery.     
8.5 Remission Duration 
Only patients achieving CR or CRp or CRi are assessed for remission duration. Remission 
duration is measured from the date of achievement of a remission until the date of relapse or death from any cause; patients not known to have relapsed or died at last follow-up will 
be censored on the date of their last tumor assessment.   
 
8.6 Morphologic Leukemia-free State 
All registered patients that have at least one evaluable post registration bone marrow 
assessment performed on or after Day 14 after the last induction will be assessed for 
morphologic leukemia-free state.  Morphologic leukemia-free state is defined as bone marrow blasts <5% AND absence of Auer rods and/or extramedullary disease.
1 
 
8.7 Stem Cell Transplant 
The number and percentage of patients transferred for stem cell transplant will be 
summarized. 
 
9 Assessment of Safety  
9.1 Safety Population 
All patients who receive at least one dose of study drug will be considered evaluable for 
safety.  
9.2 Adverse Events 
9.2.1 Definition of an Adverse Event 
An adverse event is any untoward medical occurrence in a patient or clinical investigation 
subject administered with a pharmaceutical product and which does not necessarily have to have a causal relationship with this trea tment. An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes worsening of a pre-existing condition or increase in frequency of a pre-existing condition. An adverse event is considered serious if it meets any of the serious criteria listed in Section 9.2.2.  To ensure no confusion or misunderstanding of the difference between the terms “serious” and 
“severe”, which are not synonymous, the following clarification is provided:  
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 31 of 50  
 The term “severe” is often used to des cribe the intensity (severity) of a specific event (as 
in mild, moderate, or severe myocardial infa rction); the event itself, however, may be of 
relatively minor medical significance (such as severe headache). This is not the same as “serious”, which is ba sed on patient/event outcome or action criteria usually associated 
with events that pose a threat to a patient’s life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  Adverse events are to be recorded in the case report form from the start of the infusion on Day 1 to the last day of the treatment period, 30 days after the last dose, with the exception 
of serious adverse events. (See Section 9.2.2).  Adverse drug reactions (ADRs) are all noxious and unintended responses to a medicinal product related to any dose that a causal relationship between the medicinal product and 
an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled 
out. An unexpected ADR is any adverse reaction not identified in nature or intensity in the 
current Investigator’s Brochure.  
 
9.2.2 Definition of a Serious Adverse Event 
A serious adverse event (SAE) is any adverse event that: 
 
Results in death (grade 5) Is life-threatening Requires inpatient hospitalization or prolongation of existing hospitalization Results in persistent or significant disability or incapacity Is a congenital anomaly/birth defect 
 
These events are to be reported as serious from the start of the infusion on Day 1 to 30 days after completion of the treatment period.  Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one 
of the events listed above. 
 
9.2.3 Serious Adverse Event Reporting Instructions 
The investigator must complete the Serious Adverse Event Report Form in English, assess 
the relationship to study treatment and send the completed form by fax within 24 hours to 
the Sponsor or its designee.  The original and the duplicate copies of the Serious Adverse 
Event Form, and the fax confirmation sheet must be kept with the case report forms at the study site.  Follow-up information should be sent to the Sponsor or its designee via the original Serious Adverse Event Form, re-stating the date of the original report.  Either a new Serious Adverse Event Form should be sent (stating that this is a follow-up), or the original one 
resent (with the new information highlighted and a new date provided).  The follow-up 
should describe whether the event has resolved or continues, if and how it was treated, 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 32 of 50  
 whether the patient continued or disconti nued study participation.  The form and fax 
confirmation sheet must be retained.  The telephone and fax numbers of the local Clinical Research contact person and the contact person in the local department of Clinical Safety, specific to the site, must be listed in the investigator folder prov ided for each individual site and provided to the Sponsor or 
its designee at the start of the trial.  Questions referring to a specific serious adverse event occurring in a study patient should be directed to the local Clinical Research contact person specified in the investigator folder provided for the site.  
9.2.4 Reporting Serious Adverse Events to Regulatory Agencies and Review Boards 
All SAEs must be reported to Jazz Pharmaceuticals, Inc. within 24 hrs of awareness, 
irrespective of relatedness, causality, expectedness. The WCM research team will complete 
and submit the US-FDA Form 3500A (MedWatch form) to AEreporting@jazzpharma.com  
within 1 business day of the awareness of the SAE.  
  All AEs and SAEs will be reported to the WCM IRB per the policies outlined below:  All SAEs will be reported with an SAE cover sheet that documents relatedness, expectedness, and risk determination. SAE reports will be saved in the study’s regulatory binder. SAE reports will be compiled to complete the Data and Safety Monitoring Board (DSMB) periodic report.  The WCM IRB must be notified within 7 calendar days of investigator notification of an 
SAE when all of the following conditions are met, as determined by the Principal 
Investigator. These SAEs are considered “immediately reportable”:  
 
a. The event is unexpected – when its specificity and severity are not accurately 
reflected in the WCM consent document, Investigators Brochure, or package insert; AND 
b. The harm is “related” or “possibly related” –  where there is a reasonable possibility 
that the harm may have been caused by the research procedure(s), or interventions; AND 
c. The harm suggests that the research places WCM subjects at greater risk of harm 
(including physical, psychological, economic or social harm) than was previously known or recognized. 
 
For events that are considered immediately reportable to the WCM IRB, the SAE report must be emailed to irb@med.cornell.edu.  AEs grade 3 or higher and all SAEs will be listed on the Adverse Event & IND Safety Reporting Cumulative Table and reported to  the WCM IRB at the time of continuing 
renewal. 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 33 of 50  
 All AEs that are serious, unexpected and associated with the use of CPX-351 will be 
reported to the applicable regulatory authority (FDA in the US and to Health Canada in 
Canada).  The period we have to report the SAE to the FDA depends on the severity of the 
SAE, as follows:  
 
- Within 7 days of becoming aware of the SAE for fatal (Grade 5), life-threatening 
(Grade 4) events  
 
- Within 15 days  of becoming aware of all other qualifying SAEs (i.e., 
hospitalizations, second cancers, etc.)  
 
9.3 Cardiac Toxicity Monitoring 
As anthracyclines are known to have an adverse effect on cardiac function, each patient’s 
cardiac function will be monitored through the treatment and follow-up phases and LVEF below 50% will be recorded as an adverse event. Any decrease in LVEF >10% resulting in a nadir LVEF <50% will be reported as an SAE.  
 
9.4 Laboratory Data 
Laboratory data obtained according to the schedule of assessments will be recorded on the 
CRF or other data collection instrument. Only laboratory data requested by the protocol should be recorded unless specific findings result in a clinical event such as an adverse event or documentation of peripheral blood count recovery.  These results will be collected and recorded on the CRF.  
10 Other Evaluations 
10.1 Blessed Orientation-Memory-Concentration Test (BOMC) 
This is a short six item test designed to evaluate older patients for early dementia.  The 
assessment is not affected by age or educational level.  The six-item Blessed Orientation-Memory-Concentration (BOMC) test was developed by Katzman, Brown, Fuld, et al. (1983) from the longer (29-item) Blessed Information-Memory-Concentration (BIMC) test (Blessed, Tomlinson, and Roth, 1968). Katzman and colleagues (1983) selected 6 of the original 29 BIMC items based on a series of statistical analyses. The scores from each of the six items are multiplied as detailed below to yield a weighted score. Possible total scores on the BOMC range from 0 (all items answered correctly) to 28 (all items answered incorrectly). Weighted error scores greater than 10 are consistent with dementia, according 
to Katzman et al. (1983). 
10.2 Montreal Cognitive Assessment (MOCA) 
The MoCA test is a one-page 30-point test administered in approximately 10 minutes. The 
test and administration instructions are freely accessible for clinicians at www.mocatest.org . The test is available in 35 languages or dialects. There are 3 alternate 
forms in English, designed for use in longitudinal settings. 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 34 of 50  
 The MoCA assesses several cognitive domains. The short-term memory recall task (5 
points) involves two learning trials of five nouns and delayed recall after approximately 5 minutes. Visuospatial abilities are assessed using a clock-drawing task (3 points) and a three-dimensional cube copy (1 point). Multiple aspects of executive functions are assessed using an alternation task adapted from the trail-making B task (1 point), a phonemic fluency task (1 point), and a two-item verbal abstraction task (2 points). Attention, concentration and working memory are evaluated using a sustained attention task (target detection using tapping; 1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each). Language is assessed using a three-item confrontation naming task with low-familiarity animals (lion, camel, rhinoceros; 3 points), repetition of two syntactically complex sentences (2 points), and the aforementioned fluency task. Finally, orientation to time and place is evaluated (6 points).  
10.3 The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) 
The FACT-Leu is a validated measurement of  quality of life parameters for patients 
undergoing treatment for acute leukemia. This questionnaire is standardly used in leukemia treatment protocols to measure quality of life parameters.  
10.4 Medical Resource Use 
Medical resource use (MRU) data will be collected for all study participants and analyzed 
by health outcomes (overall survival and response (CR+CRp+CRi) for CPX-351. The MRU data collected in the trial will be used  to identify costs associated with planned 
induction and consolidation treatment and for unplanned medical interventions necessary for patient support. Specific MRU data collected will include but may not be limited to: 
x hospitalization nights (general ward and intensive care);  
x blood product support (PRBC, Platelets, other);  
x non-chemotherapy drugs (anti-infectives, growth factors, etc.); and  
x AML chemotherapy (induction vs. consolidation).  
 
11  Statistical Considerations 
The primary objective of this non-randomized open label study is to evaluate the safety 
and efficacy of CPX- 351 as a treatment for AML in elderly ( ≥ 60 years of age) patients. 
Dose reductions or protocol closure will be considered:   
1) If >2 of the first 5 patients or >3 of the fi rst 15 patients experience grade 4 toxicities, 
accrual will stop, the protocol reviewed, and dose modifications considered. If the 
incidence of grade 4 toxicity exceeds 20% of patients at any point after the first 15 
patients have been treated, accrual will stop, the protocol will be reviewed, and dose modifications considered. 
  
2)  If 30-day mortality exceeds 20% (>3 of the initial 15 patients), all further accrual 
will stop.  Subsequent enrollment after the first 15 subjects should ideally resume 
after the safety analysis is complete, however recognizing the acute nature of AML, 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 35 of 50  
 it might not be possible to deny treatment to subjects in screening for ethical reasons 
sufficiently long to evaluate safety or efficacy. In other words, if the 30-day mortality for the preceding patients is less than 20%, study accrual will continue during the DSMB’s safety analysis.  
 
In the event that more than 15 subjects have enrolled before the safety analysis, only the first 15 subjects dosed will be informative for determining need for dose reduction as outlined above. 
 
Patients who die within the first 7 days beca use of leukemia related toxicity will be 
replaced.  Those patients will be included in the analysis given the intention to treat for 30 day mortality and overall survival.   
Analyses will primarily be descriptive in nature.  Categorical variables will be summarized 
as frequency counts with associated percentages and continuous variables will be summarized as mean, standard deviation, median and range.  Exact confidence intervals will be computed using the Clopper-Pearson method.  All analyses will be performed using SAS version 9.2 or higher.  Additional details regarding statistical analyses may be presented in a Statistical Analysis 
Plan (SAP). 
 
11.1 Primary and Secondary Endpoints 
11.1.1  Primary Endpoints 
In the CPX-351 cohort, the primary efficacy endpoint is overall survival (OS) as defined 
in Section 8.2; the primary safety endpoint is the 30-day mortality rate.     
11.1.2  Secondary Endpoints 
Secondary efficacy endpoints include complete response (CR, CRp, CRi, and 
CR+CRp+CRi), the relationship of cognitive f unction to treatment response and OS, event-
free survival and morphologic leukemia free state (as defined in Section 8).   Secondary safety endpoints include incidence of AEs and SAEs, laboratory measurements (hematology and biochemistry), vital signs and physical examinations.  
11.2 Sample Size and Power Justification for Primary Endpoint 
With 24 months for accrual, and a minimum of 36 months of follow-up, using a one-sided 
alpha-level of 0.05, a sample size of 30 patients has 80% power to detect a difference between the null hypothesis of 10 months median survival versus 16 months median survival in this patient population.  In regards to safety, with a sample size of 30 the maximum width of the one-sided 95% 
exact confidence interval for estimated 30-day or 60-day mortality rates is less than 19%. 
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 36 of 50  
 Analysis of the relationship of cognitive function to outcome and overall survival will be 
hypothesis generating.   
11.3 Analysis Populations 
 
Efficacy and safety analysis populations will be comprised of all patients who receive at least one dose of study drug.   
11.4 Analysis of Primary Endpoints 
 
Overall survival will be analyzed using Kaplan-Meier methods. Patients who have not died at the time of analysis will be censored on the date they were last known to be alive.  
Median survival and the associated 95% confidence interval will be computed using the 
Brookmeyer-Crowley method.  The estimated survival curve will be generated.  Estimates of 30- and 60-day mortality rates will be computed using Kaplan-Meier methods along with associated two-sided 95% co nfidence intervals computed using the 
Brookmeyer-Crowley method.    
11.5 Analysis of Secondary Endpoints 
 
Time dependent endpoints, such as remission duration (relapse-free survival) and event-free survival (EFS), will be evaluated using Kaplan-Meier methods; estimates of event rates will be computed and a survival curve generated.    
 
Binary Endpoints 
 
The response (CR, CRp, CRi, and CR+CRp+CRi) rate and best response (CR, CRp, CRi, and CR+CRp+CRi) rate will be calculated based on the responses achieved as defined in section 8.4. The number of patients who achieve response will be divided by the number of patients in the efficacy population to determine response rate.  
 
Likewise, the morphologic leukemia-free rate will be calculated as the number of patients who achieve morphologic leukemia-free state, as defined in section 8.6, divided by the number patients in the safety population who have at least one evaluable post-randomization bone marrow assessment. 
 
The rate of stem cell transplant will be calculated by the number of patients who have a stem cell transplant divided by the number of patients in the safety population.  
11.6 Safety Analysis 
 
Safety data will be analyzed and reported for all patients who receive at least one dose of 
study drug.  Safety data summarized will include hematology, chemistries, vital signs, 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 37 of 50  
 adverse events (AEs) and physical examinations.  Safety data will be summarized using 
descriptive statistics.    The number and proportion of patients with reported AEs and SAEs will be summarized by maximum grade.  AEs that are related to study drug will be summarized in a separate table.  Laboratory values will be summarized both by actual result and by CTC toxicity grade (for selected laboratory parameters).  Summaries of laboratory results at each scheduled time point will reflect the observed value at that ti me point as well as change from baseline. For 
selected laboratory parameters, the maximum grade for each patient will be summarized for each type of toxicity; a shift table will reflect baseline toxicity grade versus maximum observed on-treatment toxicity grade. 
 
Vital signs and physical exam data will be summarized at each scheduled time point.  
11.7 Data Safety Monitoring Board (DSMB) 
 
Weill Cornell Medical College requires that all research approved by the WCMC IRB 
include an appropriate plan for the monitoring of data to ensure the safety of human subjects. Research supported by Federal agencies will be monitored according to all regulations and guidelines of the relevant Federal agency.  
 
The WCMC Data and Safety Monitoring Board (DSMB) will review the IRB approved 
protocol, informed consent documents, and data and safety monitoring plan prior to study 
initiation. During the course of the study, the DSMB will perform safety analysis as 
outlined in 4.2 after 15 subjects have enrolled.   After the initial safety analysis period, the DSMB will review the cumulative study data semiannually to evaluate safety, efficacy, study conduct, and scientific validity and integrity of the trial. In particular, the results of the Day 30 echocardiogram will be included in the DSMB Periodic Reports. The WCMC DSMB may also convene as needed if stopping criteria are met or other safety issues arise that the Principal Investigator and/or IRB would like the WCMC DSMB to address. The study PI will submit all written DSMB recommendations to the IRB upon receipt.  
12  Administrative, Regulatory and Ethical Issues  
12.1 Direct Access to Source Documents 
Source data is all information, original records of clinical findings, observations, or other 
activities in a clinical trial ne cessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents.  Examples of these original documents and data records include but are not limited to: hospital records, clinical and office charts, 
laboratory notes, memoranda, patients’ diaries or evaluation checklists, pharmacy 
dispensing records, recorded data from automated instruments, copies or transcriptions 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 38 of 50  
 certified after verification as being accurate and complete, microfiches, photographic 
negatives, microfilm or magnetic media, x-rays, patient files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial.  All data will be collected and stor ed on a computerized database using a REDCAP 
program.   Case report forms, all copies of test results, and study-related regulatory documents [e.g., Informed Consents, Institutional Review Board (IRB)/Ethics Committee (EC) approvals/correspondence, etc.] must be available at all times for regulatory agency inspection and review by the sponsor or its designee. During the periodic site monitoring visits, the source documents will be verified against data entered onto the CRF in order to assure that all data is accurately and completely reflected on the patient's CRF.  
12.2 Study Monitoring and Quality Inspections/Audits 
 
This study will be monitored by the WCM PI and/or research team according to GCP/ICH guidelines.  An internal site initiation visit will be held prior to initiation of patient enrollment. The protocol, CRFs, study drug supplies, and relevant procedures will be explained in detail at the site visit. Subseque nt to patient enrollment, the WCM PI and/or 
research team will review the CRFs and source documents to ensure that the study is conducted according to the protocol and GCP/ICH guidelines.    To ensure compliance with GCP/ICH guidelines and all applicable regulatory requirements, WCM PI and/or research team may conduct an internal quality assurance audit.  Regulatory agencies may also conduct a regulatory inspection of this study.  Such 
audits or inspections can occur at any time during or after completion of the study.  If audits 
or inspections occur, the WCM PI and WCM’s resear ch team agree to allow the 
auditor/inspector direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any relevant issues.  
 
12.3 Ethics 
This study will be conducted in accordance with local regulations, GCP, ICH guidelines 
and the Declaration of Helsinki. The WCM PI will be responsible for the overall conduct of the clinical trial for the site and will be responsible for ensuring the trial is conducted according to the protocol and all regulatory requirements and IRB/EC regulations.  
12.4 Adherence to the Protocol 
Except for a change that is intended to elim inate an immediate hazard to patients, the 
approved protocol will be conducted as described.  If a change in the conduct is made to eliminate an immediate hazard, the FDA and IRB/EC are notified immediately.  Deviations from the protocol will be considered in two categories, Protocol Violations and Protocol Deviations.  Protocol Violations include patients who are not eligible according 
to the inclusion/exclusion criteria in effect at the time of registration.  Protocol Deviations 
include other non-compliance with the protocol, such as missing or skipped procedures or 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 39 of 50  
 evaluations, evaluations performed outside given window, incorrect administration of 
investigational product, etc.  
12.5 Protocol Revisions 
All revisions must be discussed with, and be prepared by, the WCM PI.  If the revision is 
an Administrative Letter, the investigator shou ld submit it to the IRB/EC and FDA for their 
information.  If the revision is an Amendment, it will be signed by the WCM PI.  The WCM PI must submit the Amendment to the IRB/EC for review and approval prior to implementation.  Documentation of approval signed by the Chairperson or designee of the IRB/EC must be sent to the FDA.  If an Amendment substantially alters the study design or increases the potential risk to the 
patient: (1) the consent form must be revised and submitted to the IRB/EC for review and 
approval; (2) the revised form must be used to obtain consent from patients currently enrolled in the study if they are affected by the Amendment; and (3) the new form must be used to obtain consent from new patients prior to enrollment. The revised consent form must then also be submitted to the FDA for review and approval.  All revisions will be sent to the national competent authorities in North America.  
12.6 Retention of Patient Records and Study Files 
CRFs and other reports (e.g., investigator trial files, source documents, original, 
signed/dated informed consent forms) pertaini ng to this clinical investigation must be 
maintained for a minimum of 2 years.  
 
12.7 Patient Confidentiality 
The WCM PI and research team will preserve the confidentiality of all patients taking part 
in this trial. In the event of patient names inadvertently appearing on the trial documentation, this information will not be entered into the computer database for this trial. The WCM PI and research team will seek access to clinical information only after approval to do so has been given by the patient and the relevant authorities. The data from 
this trial may be used in publications and submissions to regulatory authorities. 
 Information about study patients will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act (HIPAA).  Those regulations require a signed patient authorization informing the patient of the following: 
What protected health information (PHI) will be collected from patients in this study 
Who will have access to that information and why Who will use or disclose that information  The rights of a research patient to revoke their authorization for use of their PHI:   
In the event that a patient revokes authorization to collect or use PHI, the Investigator, by regulation, retains the ability to use all information collected prior to the revocation of 
patient authorization.  For patients that have revoked authorization to collect or use PHI, 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 40 of 50  
 attempts should be made to obtain permission to collect at least vital status (i.e. that the 
patient is/is not alive) at the end of their scheduled study period.  
12.8 Informed Consent 
Patients will be required to sign a stateme nt of informed consent that meets the 
requirements of the US Code of Federal Regulations (21 CFR 50), Canadian regulations, local regulations, ICH guidelines and the IRB/EC of the study center. The medical record will include a statement that written informed consent was obtained before the patient was 
enrolled in the study and the date written consent was obtained.  Members of the treating team will review the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits and alternative 
therapies including best supportive care. Patients must be informed that participation in the 
study is voluntary, he/she may withdraw from the study at any time and withdrawal from the study will not affect his/her subsequent medical treatment or relationship with the treating physician. Financial costs that will or may be incurred as a result of participation in the study, as well as the efforts to maintain  patient confidentiality will also be discussed. 
 This consent must be witnessed and dated and retained by the WCM PI as part of the study records.  A copy of the informed consent form must be given to the patient.  In the event the patient is re-screened, the patient is not required to sign another informed consent form unless the patient is re-screened more than 30 days from the previous informed consent form signature date.  If an Experimental Subject's Bill of Rights is applicable in the Investigator’s US state, that 
form must also be prepared and signed by each patient and retained as a part of the required 
study records.  A copy of the Bill of Rights must be given to the patient or the patient's legally authorized representative.  A copy of the IRB approved consent form must be submitted to the FDA and Jazz Pharmaceuticals, Inc. prior to shipment of drug supplies to WCM.  Each patient's signed 
informed consent must be kept on file by the Investigator for regulatory authority 
inspection at any time.  For all US sites, the HIPAA Privacy Rule Auth orization language must be included in the 
Informed Consent/authorization form (or a separate authorization document) and approved by the IRB (or Privacy Board).  The elements of the HIPAA Privacy Rule Authorization 
are found in APPENDIX 5:  Elements of the HIPAA Privacy Rule Authorization. 
 The Declaration of Helsinki, as amended, recommendations (2008 version), guiding doctors in clinical research must be signed by the Investigator and returned to the Sponsor or its designee.  A copy must also be kept on file by the Investigator. The IRB/EC of an institution must approve the consent form document to be used at that center prior to its local activation; changes to the consent form during the course of the 
study will also require IRB/EC notification/approval. 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 41 of 50  
  
The following elements must appear in the consent form: a description of the purpose of the study (indication, that the drug is investigational); potential side effects; potential benefits; study design; voluntary participation; and confidentiality.  It is essential that the consent form contain a clear statement that gives permission for 1) information to be sent to and 2) source medical records to be reviewed by the Sponsor and other agencies as necessary.  
12.9 Publication Policy 
The results of this study will be published by the study investigator and sub-investigators.   
 The Sponsor requires review of written and oral pr esentation at least 45 days prior to initial 
submission to the publishing authority.  If necessary to protect proprietary rights of 
information to be disclosed in the publication, the Sponsor may request a further 45 day delay in submission for publication, and the investigators agree to make all reasonable efforts to grant such further delay to the Sponsor. 
  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 42 of 50  
 13 References 
 1. Dohner H, Estey EH, Amadori S, et al: Diagnosis and management of acute 
myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-74, 2010  2. Stone RM, O'Donnell MR, Sekeres MA: Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program:98-117, 2004  3. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-5, 2006  4. Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106:1090-8, 2006 
 5. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of 
the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-9, 2003  6. Estey E: Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25:1908-15, 2007  7. Hiddemann W, Kern W, Schoch C, et al: Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17:3569-76, 1999  8. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-24, 2007  9. Burnett AK, Milligan D, Goldstone A, et al: The impact of dose escalation 
and resistance modulation in older patients with acute myeloid leukaemia and high risk 
myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 145:318-32, 2009  10. Lowenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235-48, 2009 
 11. Fernandez HF, Sun Z, Yao X, et al: Anthracycline dose intensification in 
acute myeloid leukemia. N Engl J Med 361:1249-59, 2009  12. Cassileth PA, Harrington DP, Hines JD, et al: Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6:583-7, 1988  13. Leone G, Mele L, Pulsoni A, et al: The incidence of secondary leukemias. 
Haematologica 84:937-45, 1999 
 14. Sekeres MA, Elson P, Kalaycio ME, et al: Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood 113:28-36, 2009  15. Mayer LD, Harasym TO, Tardi PG, et al: Ratiometric dosing of anticancer drug combinations: controlling drug ratios af ter systemic administration regulates 
therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5:1854-63, 2006 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
 
CONFIDENTIAL  Page 43 of 50  
  16. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations 
for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 18:3558-85, 2000  17. Schoenfeld D: The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 68:316-319, 1981  18. Swerdlow SH CE, Harris NL: WHO Classification of Tumours of Haematopoitic and Lymphoid Tissues. Lyon, IRAC Press, 2008  
 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 44 of 50  
  
14 APPENDIX 1: Patient Evaluation Flow Sheet – Treatment Phase 
Each INDUCTION1, 2 and CONSOLIDATION: 
Day:  Screening 1 2 3 4 5 6 7 
±3 10 
±1 14 
±2 21
±2 28
±2 35
±2 42 
±2 Weekly3 
±2 1508 
±10 End of Phase/Early 
Term. ±30 
Informed Consent4 x                 
Medical/Leukemia History x                 
Physical Exam x         x    x    
Vital Signs x         x    x    
ECOG Performance Status x                 
ECG x x8              x x8 
Registration x                 
Hematology x x  x  x  x x x x x x x x   
Biochemistry x x  x  x  x x x x x x x x   
Urinalysis x                 
Bone Marrow Evaluation x         x5 As needed to confirm response/persistence 
Chest X-ray/Chest CT x             
Echocardiography/MUGA/cardiac 
MRI x             x7  x x 
Blessed Orientation Memory 
Concentration x9       x9      x9   x9 
MOCA x9       x9      x9   x9 
FACT-Leu x9       x9      x9   x9 
Response Assessment          x6        
Cytogenetics/Molecular Studies x At the time of CR or CRi  
Adverse Events  Assess throughout Induction and Consolidation   
Concomitant Medications  Assess throughout Induction and Consolidation   
Treatment Administration CPX-351  See relevant protocol section(s).  x 
1The first induction may end prematurely if a second induction is necessary, see Section 4.4.  The schedule of evaluations for t he first induction is followed until the second induction starts, then the 
evaluations are followed as indicated in  the flow sheet, beginning with Day 1 
2 Second inductions and consolidations of are CPX-351 on Days 1 an d 3, see Sections 4.4 & 4.5, See Section 7 for an alternative consolidation regimen of intermediate dose cytarabine, e.g.  for patients 
that exceed  500mg/m2 cumulative daunorubicin-equivalent dose, or as decided by the investigator 
3Continue weekly evaluations until confirmation of response (CR/CRi) or persistent disease is declared 
4 Within 30 days prior to start of screening, if informed cons ent was collected, 30 days elapse and the patient is still not scre ened he/she must sign another ICF 
5Required after first induction  (in case the Day 14 bone marrow is non-evaluable or assessment of aplasia is equivocal, a repeat evaluation may be performed 5- 14 days later, at the discretion of the 
treating physician, in order to determine effect and need for second induction  
6Day 150 or 45 Days after the last treatment whichever is later 
7See Section 9.3, Repeat ECHO/MUGA/cardiac MRI before the second consolidation  
8 ECG will be performed pre-dose for each course of tr eatment, and at the end of each course or EOT.  
9 Blessed, MOCA and FACT-Leu can be administered +/- 3 days from indicated day   
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 45 of 50  
 15 APPENDIX 2: Patient Evaluation Flow Sheet –Follow-up 
 Monthly for 1 Year 
(±10 Days) Once 
Years 2-5 Early 
Termination 
Patient status report x x x 
Hematology x  x 
Biochemistry Perform monthly only if abnormality(ies) 
persists at the end of the Treatment Phase.  
Perform until abnormality(ies) returns to baseline, until 1 year from registration, or the initiation of new therapy and/or relapse. 
(whichever is earliest)   
Bone Marrow 
Aspiration/Biopsy  For patients in CR or CRi perform at any 
time that there is a su spicion of relapse. For 
patients in CR, perfor m if peripheral blood 
counts fall below 1000/ μL for ANC or 
100,000/μL for platelets for >1 month or at 
any time there is suspicion of relapse. For 
patients in CRi perform if counts fall 
significantly below peak recovery levels.  If the peripheral blood counts in a patient with a CRi recover to CR levels ( ≥1000/μL for 
ANC or ≥100,000/μL for platelets), perform 
a bone marrow evaluation within 14 days to 
confirm CR.  Following the first year of 
follow up, record relapse information, including any bone marrow evaluations.  Not required following the initiation of new therapy and or relapse.    
Echocardiography, MUGA or 
Cardiac MRI If last LVEF treatment phase or Day 150 
was reduced >10% from baseline and is less 
than 50% repeat every 3 months until LVEF returns to baseline (±5%) or until 1 year from registration.  Persistent reductions in LVEF of >10% with nadir values below 50%
 documented at 1 year are considered 
permanent sequelae.   
Adverse Events/Toxicity Assess AEs that were ongoing at the time of 
discontinuation. Do NOT record any new 
AEs.  AEs that persist without evidence of 
recovery for >30 days are considered permanent
 sequelae and do not require 
further follow-up.   
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 46 of 50  
 16 APPENDIX 3: Performance Status – ECOG 
 
Grade Description 
0 Fully active, able to carry on all pre-disease performance without 
restriction (Karnofsky 90-100) 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature (e.g., light housework, office work) (Karnofsky 70-80). 
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities.  Up and about more than 50% of waking hours (Karnofsky 50-60). 
3 Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours (Karnofsky 30-40). 
4 Completely disabled.  Cannot carry on any self-care.  Totally confined 
to bed or chair (Karnofsky 10-20). 
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 47 of 50  
 17 APPENDIX 4: Common Terminology Criteria for Adverse Events 
V4.0 (CTCAE) 
 
This 72 page document can be obtained as a pdf file from http://ctep.cancer.gov . 
The publication date is June 14, 2010  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 48 of 50  
 18 APPENDIX 5:  Elements of the HIPAA Privacy Rule Authorization 
x Written in plain language underst andable to the patient or the 
representative;  
x A “specific and meaningful” description of Protected Health Information 
(PHI) to be used and disclosed;  
x The specific identification of the person/class authorized to make the use or 
disclosure;  
x The specific identification of the persons/class to whom the covered entity 
may make the requested use or disclosure;  
x Description of the purpose of the disclosure;  
x An expiration date or event (i.e., “no expiration date” for data repository 
use, or “for the duration of a specific research study” permits use until end of study plus time for wrapping up and reporting);
 
x A statement of the patient’s right to revoke the authorization and any 
exceptions to the right to revoke;  
x Conditions, if any, on authorization;  
x A statement about possible re-disclosures of PHI by the recipient and that 
the PHI will no longer be protected by the Privacy Rule in the event of such re-disclosures; and
 
x The signature and date of the patient (or of the patient’s personal 
representative, along with the personal repres entative’s authority to act).  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 49 of 50  
 19 APPENDIX 6:  Declaration of Helsinki 
WORLD MEDICAL ASSOCIATION DECLARATI ON OF HELSINKI ETHICAL PRINCIPLES 
FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (Available at http://www.wma.net/en/20activities/10ethics/10helsinki/) 
  
  
 PROTOCOL #CEL11001 
CPX-351 (cytarabine:daunorubicin) Liposome Injection 25-JUN-2018, Version 5.0 
CONFIDENTIAL  Page 50 of 50  
  
20 APPENDIX 7: Anthracyclines Equivalents Guidelines 
According to the exclusion criteria patients  with a total lifetime anthracycline 
exposure exceeding the equivalent of 368 mg/m2 of daunorubicin (or equivalent) 
prior to start of study therapy [100 u/m2 of CPX-351 contains 44 mg/m2 of 
daunorubicin x 3 doses (1 induction) = 132 mg/m2 + 368 mg/m2 = 500 mg/m2 = 
maximum allowable limit of daunorubicin from all sources at the end of the 1st induction] are excluded from Protocol CLTR0310-301.   
  Conversion factor* 
Daunorubicin 1 
Doxorubicin 2 
Epirubicin 1 
Idarubicin 4 
Mitoxantrone 4.4 
 Multiply the number in the second column by the total cumulative dose a patient 
has received. 
 For example: 200mg/m
2 of mitoxantrone x 4.4(conversion factor) = 880mg/m2  
This means 200mg/m2 of mitoxantrone is equivalent to 880 mg/m2 of daunorubicin  
 *Adapted from Keefe D., Anthracycline-Induced Cardiomyopathy. Seminars in 
Oncology, Vol 28, No 4, Suppl 12 (August), 2001: pp 2-7  
 
 